Arrowstreet Capital
RCUS icon

Arrowstreet Capital’s Arcus Biosciences RCUS Stock Holding History

Arrowstreet Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-239,420
Closed -$3.26M – 1986
2025
Q3 		$3.26M Buy
+239,420
New +$2.49M ﹤0.01% 1324
2021
Q1 		– Sell
-122,773
Closed -$3.19M – 2478
2020
Q4 		$3.19M Sell
122,773
-60,616
-33% -$1.47M ﹤0.01% 1409
2020
Q3 		$3.14M Buy
183,389
+104,860
+134% +$2.34M 0.01% 1362
2020
Q2 		$1.94M Buy
+78,529
New +$2.12M ﹤0.01% 1496

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Arrowstreet Capital's RCUS Position: Q4 2025 in Review

Arrowstreet Capital sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 239,420 shares — an estimated $3.26M sold.

Arrowstreet Capital first reported a position in RCUS in Q2 2020 and held it in 4 quarters. The position peaked at $3.26M in Q3 2025. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • Arrowstreet Capital reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 239,420 Arcus Biosciences shares in Q4 2025, an estimated $3.26M.
  • Arrowstreet Capital first reported a position in Arcus Biosciences in Q2 2020 and held it in 4 quarters.
  • Arrowstreet Capital's Arcus Biosciences position peaked at $3.26M in Q3 2025.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Arrowstreet Capital's 13F filing for Q4 2025, filed 13 Feb 2026.